Amryt Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao downgraded Amryt Pharma to Neutral from Buy with a price target of $14.50, down from $18, after the company announced last week that it has agreed to be acquired by Chiesi. His new price target of $14.50 is based on the acquisition price agreed with Chiesi Farmaceutici.